Biomarkers in Cardiorenal Syndromes

There is a consensus that cardiorenal syndromes (CRS) are defined as the disorders of heart and kidney where acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in another. Patients with CRS have increased hospitalization and mortality rates, and thus their identificati...

Full description

Bibliographic Details
Main Authors: Shihui Fu, Shaopan Zhao, Ping Ye, Leiming Luo
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2018/9617363
id doaj-bc2089c9347249e5af6691d04de3d908
record_format Article
spelling doaj-bc2089c9347249e5af6691d04de3d9082020-11-24T22:56:58ZengHindawi LimitedBioMed Research International2314-61332314-61412018-01-01201810.1155/2018/96173639617363Biomarkers in Cardiorenal SyndromesShihui Fu0Shaopan Zhao1Ping Ye2Leiming Luo3Department of Geriatric Cardiology, Chinese People’s Liberation Army General Hospital, Beijing 100853, ChinaDepartment of Geriatric Cardiology, Chinese People’s Liberation Army General Hospital, Beijing 100853, ChinaDepartment of Geriatric Cardiology, Chinese People’s Liberation Army General Hospital, Beijing 100853, ChinaDepartment of Geriatric Cardiology, Chinese People’s Liberation Army General Hospital, Beijing 100853, ChinaThere is a consensus that cardiorenal syndromes (CRS) are defined as the disorders of heart and kidney where acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in another. Patients with CRS have increased hospitalization and mortality rates, and thus their identification is of great implication. Biomarkers are not only predictive in heart failure or renal diseases, but also useful in identifying cardiac dysfunction in renal diseases and renal injury in heart failure. Thus, they may be applied in order to identify patients with CRS and even assess prognosis and guide therapy in these patients. However, studies on biomarkers have just begun in CRS. Future studies are essential to observe current biomarkers and find novel biomarkers in CRS so as to improve diagnosis, therapy, and prognosis of CRS.http://dx.doi.org/10.1155/2018/9617363
collection DOAJ
language English
format Article
sources DOAJ
author Shihui Fu
Shaopan Zhao
Ping Ye
Leiming Luo
spellingShingle Shihui Fu
Shaopan Zhao
Ping Ye
Leiming Luo
Biomarkers in Cardiorenal Syndromes
BioMed Research International
author_facet Shihui Fu
Shaopan Zhao
Ping Ye
Leiming Luo
author_sort Shihui Fu
title Biomarkers in Cardiorenal Syndromes
title_short Biomarkers in Cardiorenal Syndromes
title_full Biomarkers in Cardiorenal Syndromes
title_fullStr Biomarkers in Cardiorenal Syndromes
title_full_unstemmed Biomarkers in Cardiorenal Syndromes
title_sort biomarkers in cardiorenal syndromes
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2018-01-01
description There is a consensus that cardiorenal syndromes (CRS) are defined as the disorders of heart and kidney where acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in another. Patients with CRS have increased hospitalization and mortality rates, and thus their identification is of great implication. Biomarkers are not only predictive in heart failure or renal diseases, but also useful in identifying cardiac dysfunction in renal diseases and renal injury in heart failure. Thus, they may be applied in order to identify patients with CRS and even assess prognosis and guide therapy in these patients. However, studies on biomarkers have just begun in CRS. Future studies are essential to observe current biomarkers and find novel biomarkers in CRS so as to improve diagnosis, therapy, and prognosis of CRS.
url http://dx.doi.org/10.1155/2018/9617363
work_keys_str_mv AT shihuifu biomarkersincardiorenalsyndromes
AT shaopanzhao biomarkersincardiorenalsyndromes
AT pingye biomarkersincardiorenalsyndromes
AT leimingluo biomarkersincardiorenalsyndromes
_version_ 1725652636519104512